West Pharmaceutical Services, I

Valuation Analysis

About the Company

West Pharmaceutical Services, I en bref

West Pharmaceutical Services, I (WST) is currently trading at 285,83 € with a market capitalization of 20,2 Md €. The trailing P/E ratio stands at 43.83x, with a forward P/E of 34.31x. The 52-week range spans from 180,28 € to 293,63 €; the current price is 2.7% below the yearly high. Year-over-year revenue growth stands at +21.0%. The net profit margin stands at 16.85%.

💰 Dividende

West Pharmaceutical Services, I pays an annual dividend of 0,77 € per share, representing a yield of 0.27%. The payout ratio stands at 11.5%.

📊 Avis des analystes

14 analystes évaluent West Pharmaceutical Services, I (WST) au consensus : Achat Fort. L'objectif de cours moyen est de 312,78 €, soit un potentiel de +9.43% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 270,25 € à 348,71 €.

West Pharmaceutical Services, I : la thèse d'investissement en détail

West Pharmaceutical Services, I (WST) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 21% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 56.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Free cash flow is positive and net margins stand at 16.85%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

At a PEG of 3.17, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 26.54x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 34.31x is meaningfully below the trailing 43.83x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 93.1% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy West Pharmaceutical Services, I?

Compare top-rated brokers — low fees, trusted providers, fully regulated.